Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
The New England Journal of Medicine
|
November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Haematologica
|
October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Keith W Pratz, Jason Kaplan, Moshe Levy, et al.
Bone Marrow Transplantation
|
July 21, 2015
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML
Yeohan Song, John Magenau, Yumeng Li, et al.
Oncotarget
|
September 2, 2016
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma
Carl Koschmann, Daniel Zamler, Alan MacKay, et al.
International Journal of Hematology
|
October 26, 2023
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Lauren T Shinn, Lydia L Benitez, Anthony J Perissinotti, et al.
Blood
|
July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
Amir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.
Blood
|
December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Eytan M Stein, Roland B Walter, Harry P Erba, et al.
Blood Advances
|
December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Martin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
The New England Journal of Medicine
|
November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Haematologica
|
October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Keith W Pratz, Jason Kaplan, Moshe Levy, et al.
Bone Marrow Transplantation
|
July 21, 2015
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML
Yeohan Song, John Magenau, Yumeng Li, et al.
Oncotarget
|
September 2, 2016
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma
Carl Koschmann, Daniel Zamler, Alan MacKay, et al.
International Journal of Hematology
|
October 26, 2023
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
Lauren T Shinn, Lydia L Benitez, Anthony J Perissinotti, et al.
Blood
|
July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
Amir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.
Blood
|
December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Eytan M Stein, Roland B Walter, Harry P Erba, et al.
Blood Advances
|
December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Martin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Page
of 5